Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
NCT ID: NCT00442325
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
595 participants
INTERVENTIONAL
2003-01-31
2004-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
NCT00442845
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
NCT00644670
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
NCT00136942
Actual Use Trial of Atorvastatin Calcium 10 mg
NCT01964326
Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand
NCT00647543
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin (Lipitor)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Triglycerides up to 600 mg/dL.
* History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events.
Exclusion Criteria
* Use of other drugs that would interfere with evaluation of efficacy or cause safety problems
* Uncontrolled hypertension, diabetes or hypothyroidism
* Recent cardiac event of procedure
* High baseline CPK levels
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Ioannina, , Greece
Pfizer Investigational Site
Kallithea, Athens, , Greece
Pfizer Investigational Site
Pireaus, , Greece
Pfizer Investigational Site
Thessaloniki, , Greece
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Gyula, , Hungary
Pfizer Investigational Site
Kecskemét, , Hungary
Pfizer Investigational Site
Nyíregyháza, , Hungary
Pfizer Investigational Site
Szekszárd, , Hungary
Pfizer Investigational Site
Tullamore, CO. Offlay, Ireland
Pfizer Investigational Site
Tallaght, Dublin, Ireland
Pfizer Investigational Site
Gorey, Wexford, Ireland
Pfizer Investigational Site
Cork, , Ireland
Pfizer Investigational Site
Dublin, , Ireland
Pfizer Investigational Site
Galway, , Ireland
Pfizer Investigational Site
Częstochowa, , Poland
Pfizer Investigational Site
Poznan, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Wroclaw, , Poland
Pfizer Investigational Site
Zabrze, , Poland
Pfizer Investigational Site
Aveiro, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Vila Franca de Xira, , Portugal
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Pfizer Investigational Site
Bern, , Switzerland
Pfizer Investigational Site
Geneva, , Switzerland
Pfizer Investigational Site
Mendrisio, , Switzerland
Pfizer Investigational Site
Zurich, , Switzerland
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Farsang C, Athyros V, Gaw A; ACTFAST-2 investigators and Steering Committee members. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Curr Med Res Opin. 2007 Aug;23(8):1945-56. doi: 10.1185/030079907X223242.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581095
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.